<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003433</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066459</org_study_id>
    <secondary_id>DUMC-2031-00-11R3</secondary_id>
    <secondary_id>DUMC-2176-99-12R2</secondary_id>
    <secondary_id>DUMC-97146</secondary_id>
    <secondary_id>NCI-G98-1456</secondary_id>
    <nct_id>NCT00003433</nct_id>
  </id_info>
  <brief_title>Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer</brief_title>
  <official_title>A Phase I/II Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous, Cultured Dendritic Cells After Complete Resection of Hepatic Metastases of Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build&#xD;
      an immune response to kill their tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white&#xD;
      blood cells in treating patients with resected liver metastases from colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the cellular immune response to carcinoembryonic antigen pulsed dendritic&#xD;
           cells in patients with adenocarcinoma of the colon metastatic to the liver.&#xD;
&#xD;
        -  Evaluate the overall and recurrence free survival in this patient population.&#xD;
&#xD;
      OUTLINE: Patients undergo leukapheresis for up to 4.5 hours to collect dendritic cells. The&#xD;
      separated dendritic cells are pulsed with carcinoembryonic antigen (CEA) RNA. Patients&#xD;
      receive CEA RNA pulsed dendritic cells intravenously every 2 weeks for a total of 4 doses.&#xD;
      Patients undergo a second leukapheresis 2 weeks after the last dendritic cell infusion to&#xD;
      obtain specimens for immunologic tests. Patients with extra doses of dendritic cells&#xD;
      available may receive additional doses of CEA RNA pulsed dendritic cells every 2 months in&#xD;
      the absence of unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at weeks 12, 24, 36, and 48, and every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study over 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>carcinoembryonic antigen RNA-pulsed DC cancer vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon metastatic to the liver that&#xD;
             expresses carcinoembryonic antigen (CEA) after resection with curative intent&#xD;
&#xD;
               -  At least 50% of the tumor cells must stain positive for CEA with at least&#xD;
                  moderate intensity&#xD;
&#xD;
          -  No gross residual disease after surgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1000/mm 3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  No chronic or acute hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No chronic or acute cardiac disease (New York Heart Association class III or IV)&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No chronic or acute pulmonary illness such as asthma or chronic obstructive pulmonary&#xD;
             disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled&#xD;
             superficial bladder cancer within the past 5 years&#xD;
&#xD;
          -  No history of autoimmune disease such as inflammatory bowel disease, systemic lupus&#xD;
             erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis&#xD;
&#xD;
          -  No active acute or chronic infection such as urinary tract infection, HIV, or viral&#xD;
             hepatitis&#xD;
&#xD;
          -  No active infectious enteritis or eosinophilic enteritis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroid therapy (or any other immunosuppressives)&#xD;
&#xD;
          -  At least 6 weeks since prior steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert K. Lyerly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

